Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-07-09
1996-03-26
Kim, Kay K. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 8, 514 12, 530345, 5303911, 5303919, 5303917, 530399, 530405, 530409, A61K 3818, C07K 1702, C07K 1448
Patent
active
055020372
ABSTRACT:
Pro-cytotoxic drug conjugates for anticancer therapy comprising a homing agent first moiety, a spacer molecule second moiety covalently linked to the homing agent, and a third moiety covalently linked to the second moiety consisting of a pro-cytotoxic drug that is non-toxic extracellularly but that, after internalization of the conjugate by proliferating tumor cells, is metabolized by one or more endogenous intracellular enzymes to a cytotoxic metabolic product, so that cell growth is arrested or the cells killed. Preferred procytotoxic drugs are carboxyphosphamide or carboxyisophosphamide.
REFERENCES:
patent: 4545985 (1985-10-01), Pastan et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5087616 (1992-02-01), Meyers et al.
patent: 5120740 (1992-06-01), Elfarra
Gould et al (1989) J. Natl. Cancer Inst. 81(10):775-781.
Osband et al (1990) Immunology Today 11(6):193-195.
Kaneko et al (1991) Bioconjugate Chem. 2(3):133-141.
Bagshawe et al (1988) Br. J. Cancer 58:700-703.
Senter et al., "Generation Of Cytotoxic Agents By Targeted Enzymes", Bioconjugate Chem., vol. 4:3-9, (1993).
Svensson et al., "Monoclonal Antibody-.beta.-Lactamase Conjugates For The Activation Of A Cephalosporin Mustard Prodrug", Bioconjugate Chem., vol. 3:176-181, (1992).
Wallace et al., "In Vitro And In Vivo Activities Of Monoclonal Antibody-Alkaline Phosphatase Conjugates In Combination With Phenol Mustard Phosphate", Bioconjugare Chem., vol. 2:349-352, (1991).
Senter, "Activation Of Prodrugs By Antibody-Enzyme Conjugates: A New Approach To Cancer Therapy", The FASEB Journal, vol. 4:188-193 (1990).
Brock, "Comparative Pharmacologic Study In Vitro An In Vivo With Cyclophosphamide (NSC-26271), Cyclophosphamide Metabolites, And Plain Nitrogen Mustard Compounds", Cancer Treatment Reports, vol. 60:301-308, (1976).
Alarcon et al., "Isophosphamide As A New Acrolein-Producing Antineoplastic Isomer Of Cyclophosphamide", Cancer Research, vol. 32:2519-2523, (1972).
Hill et al., "Metabolism Of Iphosphamide 2-(2-Chloroethylamino)-3-(2-Chloroethyl)tetraphydro-2H-1,3,2-oxazaphospho rine 2-Oxide! And Production Of A Toxic Iphosphamide Metabolite", Cancer Research, vol. 33:1016-1022, (1973).
Alarcon et al., "Effects Of Diazoxide And A Dipyridamole Derivative On Cardiac Nucleotide Content", Nature New Biology, vol. 233:250-252, (1971).
Yankner et al., "The Biology And Mechanism Of Action Of Nerve Growth Factor", Ann. Rev. Biochem., vol. 51:845-868, (1982).
Rakowicz-Szulczynska, "Identification Of The Cell Surface And Nuclear Receptors For NGF In A Breast Carcinoma Cell Line", Journal Of Cellular Physiology, vol. 154:64-70, (1993).
Greene et al., "PC12 Pheochromocytoma Cells: Culture, Nerve Growth Factor Treatment, And Experimental Exploitation", Methods In Enzymology, vol. 147:207-216, (1987).
Marchetti et al., "Nerve Growth Factor Receptors In Human Neuroblastoma Cells", Journal Of Neurochemistry, vol. 49:475-486, (1987).
Waldmann, "Monoclonal Antibodies In Diagnosis And Therapy", Science, vol. 252:1657-1662, (1991).
Hird et al., "Immunotherapy With Monoclonal Antibodies", Genes And Cancer, pp. 002-008, (1990).
Wilman (1986) "Prodrugs in Cancer Chemotherapy", Biochem. Soc. Trans. 14: 375-382.
Kim Kay K. A.
Neuromed Technologies, Inc.
LandOfFree
Pro-cytotoxic drug conjugates for anticancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pro-cytotoxic drug conjugates for anticancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pro-cytotoxic drug conjugates for anticancer therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-915648